Navigation Links
Rotten egg gas holds key to healthcare therapies
Date:7/9/2014

It may smell of flatulence and have a reputation for being highly toxic, but when used in the right tiny dosage, hydrogen sulfide is now being being found to offer potential health benefits in a range of issues, from diabetes to stroke, heart attacks and dementia. A new compound (AP39), designed and made at the University of Exeter, could hold the key to future therapies, by targeting delivery of very small amounts of the substance to the right (or key) places inside cells.

Scientists in Exeter have already found that the compound protects mitochondria the "powerhouse" of cells, which drive energy production in blood vessel cells. Preventing or reversing mitochondrial damage is a key strategy for treatments of a variety of conditions such as stroke, heart failure, diabetes and arthritis, dementia and ageing. Mitochondria determine whether cells live or die and they regulate inflammation. In the clinic, dysfunctional mitochondria are strongly linked to disease severity.

Professor Matt Whiteman, of the University of Exeter Medical School, said: "When cells become stressed by disease, they draw in enzymes to generate minute quantities of hydrogen sulfide. This keeps the mitochondria ticking over and allows cells to live. If this doesn't happen, the cells die and lose the ability to regulate survival and control inflammation. We have exploited this natural process by making a compound, called AP39, which slowly delivers very small amounts of this gas specifically to the mitochondria. Our results indicate that if stressed cells are treated with AP39, mitochondria are protected and cells stay alive."

Dr. Mark Wood of Biosciences, at the University of Exeter, added "Although hydrogen sulfide is well known as a pungent, foul-smelling gas in rotten eggs and flatulence, it is naturally produced in the body and could in fact be a healthcare hero with have significant implications for future therapies for a variety of diseases."

The research is being conducted in several models of disease, and pre-clinical results are promising. For example, in models of cardiovascular disease, research shows that more than 80 per cent of the powerhouse mitochondria cells survive under otherwise highly destructive conditions, if the AP39 is administered. Professors Whiteman and Wood are now working towards advancing the research to a stage where it can be tested in humans.

The study was published in the journal Medicinal Chemistry Communications. A follow-up study, published in The Nitric Oxide Journal with collaborators from the University of Texas Medical Branch, also found that the compound selectively prevented mitochondrial DNA in mitochondria. Once damaged, this DNA cannot be repaired, leaving individuals more vulnerable to disease symptoms.

Early indications in small-scale studies, presented at this year's 3rd International Conference on Hydrogen Sulfide in Biology and Medicine in Kyoto, also show that in high blood pressure, AP39 reversed blood vessel stiffening and lowered blood pressure. It also dramatically improved chances of survival after a heart attack by slowing the heartbeat, improving its efficiency.


'/>"/>
Contact: Louise Vennells
l.vennells@exeter.ac.uk
44-139-272-4927
University of Exeter
Source:Eurekalert

Related medicine news :

1. FDA Says Metal-on-Metal Hip Replacements Can Cause Soft-Tissue Damage, Rottenstein Law Group Reports
2. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
3. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
4. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
5. Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group Comments on Testimony in Ongoing Robot Trial
6. Rottenstein Law Group Notes Medical Journal Article Advising Doctors To Use Caution When Prescribing Zithromax and Other Antibiotics
7. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
8. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
9. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
10. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
11. Da Vinci Surgical Robot Lawsuit News: Robot Maker Says Device Could Cause Internal Burns, Notes Rottenstein Law Group LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... METTLER TOLEDO ... place October 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers from ... dealing with today's mass calibration technologies and help with planning for the future of ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Asset Tracking and Temperature ... is as simple as scanning the bar code of the product and lot ID ... secure internet cloud where violations are automatically generated and exception alerts sent out to ...
(Date:9/25/2017)... York, NY (PRWEB) , ... September 25, 2017 ... ... , explained why retirement is not an option to senior, upper-level executives speaking ... savings account." , "A senior, high-level executive is an asset to be ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings ... shop for the hottest Korean cosmetics and fashion trends sweeping the nation. The decision ... already well-known for the great offerings that allow Koreans everywhere to look their best ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often happens ... Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s Director ... us to come over before the baby had to go back to her grandparents. ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:9/1/2017)... 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking ... — and deliver these experiences as part of Life Environments™, ... and heal better. ... While nothing beats a walk, jog or simply playing ... Environments™ is the next best thing when getting there isn’t ...
(Date:8/31/2017)... 2017 PM360,s annual Innovations Issue, published ... latest innovations happening across the industry. Established six years ... on providing a comprehensive look at the newest and ... most innovative companies, startups, divisions, products, services, and strategies ... "Everyone in this industry wants to do better—in ...
Breaking Medicine Technology: